{"id":"https://openalex.org/W4409765779","doi":"https://doi.org/10.1002/cpdd.1540","title":"Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy Participants","display_name":"Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy Participants","publication_year":2025,"publication_date":"2025-04-24","ids":{"openalex":"https://openalex.org/W4409765779","doi":"https://doi.org/10.1002/cpdd.1540","pmid":"https://pubmed.ncbi.nlm.nih.gov/40272375","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/12130360"},"language":"en","primary_location":{"id":"doi:10.1002/cpdd.1540","doi":"https://doi.org/10.1002/cpdd.1540","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.1540","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.1540","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.1540","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103575292","display_name":"Xiao\u2010Jian Zhou","orcid":"https://orcid.org/0009-0009-7662-1616","observed_orcids":["https://orcid.org/0009-0009-7662-1616"]},"institutions":[{"id":"https://openalex.org/I4210096010","display_name":"Atea Pharmaceuticals (United States)","ror":"https://ror.org/00rezvm23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210096010"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Xiao\u2010Jian Zhou","raw_affiliation_strings":["Department of Clinical Development at Atea Pharmaceuticals, Inc.  Boston MA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Development at Atea Pharmaceuticals, Inc.  Boston MA USA","institution_ids":["https://openalex.org/I4210096010"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103527855","display_name":"Gaetano Morelli","orcid":"https://orcid.org/0009-0005-8238-8751","observed_orcids":["https://orcid.org/0009-0005-8238-8751"]},"institutions":[{"id":"https://openalex.org/I4210107788","display_name":"Altasciences (Canada)","ror":"https://ror.org/01g6xse81","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210107788"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Gaetano Morelli","raw_affiliation_strings":["Clinical Research Services Altasciences Company  Quebec Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research Services Altasciences Company  Quebec Canada","institution_ids":["https://openalex.org/I4210107788"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016726584","display_name":"Maureen Montrond","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210096010","display_name":"Atea Pharmaceuticals (United States)","ror":"https://ror.org/00rezvm23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210096010"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maureen Montrond","raw_affiliation_strings":["Department of Clinical Development at Atea Pharmaceuticals, Inc.  Boston MA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Development at Atea Pharmaceuticals, Inc.  Boston MA USA","institution_ids":["https://openalex.org/I4210096010"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109731346","display_name":"Shannan Lynch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210096010","display_name":"Atea Pharmaceuticals (United States)","ror":"https://ror.org/00rezvm23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210096010"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shannan Lynch","raw_affiliation_strings":["Department of Clinical Development at Atea Pharmaceuticals, Inc.  Boston MA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Development at Atea Pharmaceuticals, Inc.  Boston MA USA","institution_ids":["https://openalex.org/I4210096010"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027950312","display_name":"Keith Pietropaolo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210096010","display_name":"Atea Pharmaceuticals (United States)","ror":"https://ror.org/00rezvm23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210096010"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Keith Pietropaolo","raw_affiliation_strings":["Department of Clinical Development at Atea Pharmaceuticals, Inc.  Boston MA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Development at Atea Pharmaceuticals, Inc.  Boston MA USA","institution_ids":["https://openalex.org/I4210096010"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029844099","display_name":"Bruce Belanger","orcid":"https://orcid.org/0000-0002-4782-5814","observed_orcids":["https://orcid.org/0000-0002-4782-5814"]},"institutions":[{"id":"https://openalex.org/I4210096010","display_name":"Atea Pharmaceuticals (United States)","ror":"https://ror.org/00rezvm23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210096010"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bruce Belanger","raw_affiliation_strings":["Department of Clinical Development at Atea Pharmaceuticals, Inc.  Boston MA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Development at Atea Pharmaceuticals, Inc.  Boston MA USA","institution_ids":["https://openalex.org/I4210096010"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104264375","display_name":"Arantxa Horga","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210096010","display_name":"Atea Pharmaceuticals (United States)","ror":"https://ror.org/00rezvm23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210096010"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Arantxa Horga","raw_affiliation_strings":["Department of Clinical Development at Atea Pharmaceuticals, Inc.  Boston MA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Development at Atea Pharmaceuticals, Inc.  Boston MA USA","institution_ids":["https://openalex.org/I4210096010"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111117309","display_name":"Janet Hammond","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210096010","display_name":"Atea Pharmaceuticals (United States)","ror":"https://ror.org/00rezvm23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210096010"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Janet Hammond","raw_affiliation_strings":["Department of Clinical Development at Atea Pharmaceuticals, Inc.  Boston MA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Development at Atea Pharmaceuticals, Inc.  Boston MA USA","institution_ids":["https://openalex.org/I4210096010"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5103575292"],"corresponding_institution_ids":["https://openalex.org/I4210096010"],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":{"value":3800,"currency":"USD","value_usd":3800},"fwci":1.9176,"has_fulltext":true,"cited_by_count":5,"citation_normalized_percentile":{"value":0.85876585,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"14","issue":"6","first_page":"461","last_page":"471"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.9750000238418579},{"id":"https://openalex.org/keywords/hepatitis-c-virus","display_name":"hepatitis C virus","score":0.7639999985694885},{"id":"https://openalex.org/keywords/ns5b-inhibitors","display_name":"NS5B inhibitors","score":0.8930000066757202},{"id":"https://openalex.org/keywords/ns5a-inhibitors","display_name":"NS5A inhibitors","score":0.9990000128746033},{"id":"https://openalex.org/keywords/food-effect","display_name":"food effect","score":0.8730000257492065},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8009999990463257},{"id":"https://openalex.org/keywords/combination-antiviral-therapy","display_name":"combination antiviral therapy","score":0.7839999794960022},{"id":"https://openalex.org/keywords/chronic-hepatitis-c","display_name":"chronic hepatitis C","score":0.722000002861023}],"concepts":[{"id":"https://openalex.org/C2777103181","wikidata":"https://www.wikidata.org/wiki/Q83141840","display_name":"NS5A","level":5,"score":0.9021713137626648},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8770663142204285},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6593335866928101},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5820558667182922},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5519871711730957},{"id":"https://openalex.org/C2776408679","wikidata":"https://www.wikidata.org/wiki/Q708693","display_name":"Hepatitis C virus","level":3,"score":0.5243556499481201},{"id":"https://openalex.org/C2781426373","wikidata":"https://www.wikidata.org/wiki/Q24766653","display_name":"NS5B","level":5,"score":0.49019700288772583},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.44894644618034363},{"id":"https://openalex.org/C3020491458","wikidata":"https://www.wikidata.org/wiki/Q131742","display_name":"Chronic hepatitis","level":3,"score":0.4257640242576599},{"id":"https://openalex.org/C2781463415","wikidata":"https://www.wikidata.org/wiki/Q2082778","display_name":"Hepacivirus","level":4,"score":0.3302127718925476},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.21733009815216064},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.15290707349777222}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006157","descriptor_name":"Guanosine Monophosphate","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D006157","descriptor_name":"Guanosine Monophosphate","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D006157","descriptor_name":"Guanosine Monophosphate","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D006157","descriptor_name":"Guanosine Monophosphate","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D012324","descriptor_name":"RNA-Dependent RNA Polymerase","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017361","descriptor_name":"Viral Nonstructural Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D018565","descriptor_name":"Food-Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1002/cpdd.1540","doi":"https://doi.org/10.1002/cpdd.1540","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.1540","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.1540","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:12130360","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12130360","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Pharmacol Drug Dev","raw_type":"Text"},{"id":"pmid:40272375","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/40272375","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology in drug development","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1002/cpdd.1540","doi":"https://doi.org/10.1002/cpdd.1540","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.1540","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.1540","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4409765779.pdf","grobid_xml":"https://content.openalex.org/works/W4409765779.grobid-xml"},"referenced_works_count":28,"referenced_works":["https://openalex.org/W2035804055","https://openalex.org/W2170104986","https://openalex.org/W2336218237","https://openalex.org/W2523593932","https://openalex.org/W2547997214","https://openalex.org/W2617761202","https://openalex.org/W2773476353","https://openalex.org/W2802032220","https://openalex.org/W2888362293","https://openalex.org/W2912664381","https://openalex.org/W2946475694","https://openalex.org/W2989571992","https://openalex.org/W2999497689","https://openalex.org/W3005839056","https://openalex.org/W3043470457","https://openalex.org/W3047275250","https://openalex.org/W3088020815","https://openalex.org/W3088908340","https://openalex.org/W3125369761","https://openalex.org/W3128729398","https://openalex.org/W3162323249","https://openalex.org/W4221003625","https://openalex.org/W4313458068","https://openalex.org/W4381308693","https://openalex.org/W4388111493","https://openalex.org/W4391157019","https://openalex.org/W4391820984","https://openalex.org/W4396661933"],"related_works":["https://openalex.org/W4408211847","https://openalex.org/W7215996794","https://openalex.org/W4410171201","https://openalex.org/W7157557311","https://openalex.org/W4399536693","https://openalex.org/W4414575052","https://openalex.org/W4391157019","https://openalex.org/W7208711199","https://openalex.org/W2797355482","https://openalex.org/W2946475694"],"abstract_inverted_index":{"A":[0,77],"combination":[1,69,198],"of":[2,19,64,103,129,149,194],"nucleotide":[3,31],"hepatitis":[4],"C":[5],"virus":[6],"(HCV)":[7],"nonstructural":[8],"protein":[9],"(NS)":[10],"5B":[11],"and":[12,62,66,73,94,112,117,170,196],"5A":[13],"inhibitors":[14],"is":[15,26],"a":[16,27,42,127,147],"preferred":[17],"standard":[18],"care":[20],"for":[21,138,200],"treating":[22,201],"chronic":[23,202],"HCV.":[24,203],"Bemnifosbuvir":[25],"novel":[28],"oral":[29],"guanosine":[30],"prodrug":[32],"with":[33,52,70,124,144],"potent":[34],"pan-genotypic":[35],"inhibitory":[36],"activity":[37,50],"against":[38],"HCV":[39],"NS5B.":[40],"Ruzasvir,":[41],"small-molecule":[43],"NS5A":[44,54,72],"inhibitor,":[45],"has":[46],"demonstrated":[47,59],"improved":[48],"anti-HCV":[49],"compared":[51],"first-generation":[53],"inhibitors.":[55],"Clinical":[56],"studies":[57],"have":[58],"favorable":[60],"efficacy":[61],"safety":[63],"bemnifosbuvir":[65,93,116,132,145,195],"ruzasvir":[67,125,139,152,197],"in":[68,81],"other":[71],"NS5B":[74],"inhibitors,":[75],"respectively.":[76],"Phase":[78],"1":[79],"study":[80,189],"healthy":[82],"participants":[83],"was":[84],"conducted":[85],"to":[86,115,158,163,175],"assess":[87],"the":[88,109,135,188],"drug-drug":[89],"interaction":[90],"potential":[91],"between":[92],"ruzasvir,":[95],"as":[96,98],"well":[97],"food":[99],"effects":[100],"following":[101],"coadministration":[102,123,143],"both":[104,159],"compounds.":[105],"Under":[106],"fasted":[107],"conditions,":[108],"peak,":[110],"trough,":[111],"total":[113,171],"exposure":[114,157,172],"its":[118],"metabolites":[119],"were":[120,140,185],"increased":[121],"upon":[122,142],"(by":[126,146,161],"maximum":[128,148],"33%":[130],"vs":[131,151],"alone),":[133],"whereas":[134],"corresponding":[136],"values":[137],"decreased":[141],"26%":[150],"alone).":[153],"Food":[154],"delayed":[155],"peak":[156,169],"drugs":[160],"up":[162,174],"2":[164],"hours)":[165],"while":[166],"increasing":[167],"their":[168],"by":[173],"63%.":[176],"No":[177],"serious":[178],"adverse":[179],"events":[180],"or":[181],"premature":[182],"drug":[183],"discontinuations":[184],"reported.":[186],"Overall,":[187],"results":[190],"support":[191],"further":[192],"evaluation":[193],"therapy":[199]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2025-04-25T00:00:00"}